Currency In USD
| Previous Close | 1.32 |
| Open | 1.58 |
| Day High | 2.06 |
| Day Low | 1.58 |
| 52-Week High | 71.5 |
| 52-Week Low | 1.07 |
| Volume | 1.03M |
| Average Volume | 77,674 |
| Market Cap | 2.88M |
| PE | -0.12 |
| EPS | -14.76 |
| Moving Average 50 Days | 3.3 |
| Moving Average 200 Days | 11.87 |
| Change | 0.42 |
Data not available
BioAtla Announces Formal Process to Evaluate Strategic Options to Monetize Assets
GlobeNewswire Inc.
Mar 02, 2026 12:30 PM GMT
SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ: BCAB or the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of
BioAtla and GATC Health Announce a $40 Million Special Purpose Vehicle (SPV) Transaction to Advance Ozuriftamab Vedotin (Oz-V) into a Registrational Trial for 2L+ Oropharyngeal Squamous Cell Carcinoma (OPSCC)
GlobeNewswire Inc.
Dec 31, 2025 12:00 PM GMT
BioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ OPSCC with the remaining $35 million anticipated to close in Q1 2026.BioAtla to retain 65% ownership of Oz-V across all solid
BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing
GlobeNewswire Inc.
Nov 21, 2025 5:25 AM GMT
These agreements are designed to be a flexible financing solution to support operations while finalizing a strategic partnershipCompany is in advanced stages to finalize a strategic transaction with a potential partner, and it remains on track to com